BioCentury | Jan 17, 2011
Product Development

Enabling patient PRPs

...has partnered an anti-gonadotropin-releasing hormone (GnRH) vaccine in Phase II testing to treat prostate cancer. Immunovo B.V....
...series A round this summer. COMPANIES & INSTITUTIONS MENTIONED Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Immunovo B.V....
BioCentury | May 10, 2010
Company News

Immunovo, Pepscan Therapeutics deal

...Pepscan granted Immunovo an exclusive, worldwide license to develop and commercialize its vaccine portfolio for an...
...commercialize its vaccine portfolio for an undisclosed cash sum and a "significant minority" stake in Immunovo...
...mimicry technology for the generation of therapeutic peptides and mAbs. Further details were not disclosed. Immunovo B.V....
BioCentury | May 3, 2010
Financial News

Immunovo completes venture financing

Immunovo B.V. , 's-Hertogenbosch, the Netherlands Business: Cancer Date completed: 4/27/10 Type: Venture financing Raised: Undisclosed Investors: BioX Biosciences BV; Lupus Ventures WIR Staff autoimmune cancer...
Items per page:
1 - 3 of 3
BioCentury | Jan 17, 2011
Product Development

Enabling patient PRPs

...has partnered an anti-gonadotropin-releasing hormone (GnRH) vaccine in Phase II testing to treat prostate cancer. Immunovo B.V....
...series A round this summer. COMPANIES & INSTITUTIONS MENTIONED Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Immunovo B.V....
BioCentury | May 10, 2010
Company News

Immunovo, Pepscan Therapeutics deal

...Pepscan granted Immunovo an exclusive, worldwide license to develop and commercialize its vaccine portfolio for an...
...commercialize its vaccine portfolio for an undisclosed cash sum and a "significant minority" stake in Immunovo...
...mimicry technology for the generation of therapeutic peptides and mAbs. Further details were not disclosed. Immunovo B.V....
BioCentury | May 3, 2010
Financial News

Immunovo completes venture financing

Immunovo B.V. , 's-Hertogenbosch, the Netherlands Business: Cancer Date completed: 4/27/10 Type: Venture financing Raised: Undisclosed Investors: BioX Biosciences BV; Lupus Ventures WIR Staff autoimmune cancer...
Items per page:
1 - 3 of 3